66th ASH Annual Meeting: 323. Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological: Poster III

Symposia: Disorders of Coagulation, Bleeding, or Fibrinolysis, Excluding Congenital Hemophilias: Clinical and Epidemiological Oral and Poster Abstracts
Poster

Research, Bleeding and Clotting, Clinical trials, Translational Research, Epidemiology, Genetic Disorders, Clinical Research, Health outcomes research, Health disparities research, Diseases, Patient-reported outcomes, Treatment Considerations, Real-world evidence, Non-Biological therapies, VWD, Registries, Study Population, Human

Halls G-H (San Diego Convention Center)

3977

Concizumab As a Possible Treatment for Bleeding Disordersof Unknown Cause

Paula Acuña¹^*, Elena Monzón Manzano, PhD¹^*, María Teresa Alvarez-Román, PhD, MD^1,2^*, Elena G Arias-Salgado, PhD¹^*, Eduardo Garcia Perez¹^*, Monica Martin Salces, PhD, MD¹^*, Maria Isabel Rivas Pollmar, PhD, MD¹^*, Rick Kapur, MD, PhD^3,4, Victor Jimenez Yuste, MD, PhD^1,2^* and Nora Butta, PhD¹^*

¹Hospital Universitario La Paz-IdiPAZ, Madrid, Spain
²Faculty of Medicine, Universidad Autonoma de Madrid, Madrid, Spain
³Department of Experimental Immunohematology, Sanquin Research, Amsterdam, Netherlands
⁴Sanquin Research and Landsteiner Laboratory, Amsterdam, Netherlands

3978

Disparities in Real-World Treatment Patterns Among Patients with Von Willebrand Disease in a Large US Population-Based Dataset

Angela C Weyand, MD¹, Michelle Sholzberg, MDCM, MSc², Jacob S Lai, PhD³^*, Benjamin Kim, MD, MPhil³, Adam Rosenthal, PhD³^*, Scott M Robertson³^*, Gary Patou, MD³^* and Robert F. Sidonio, Jr., MD, MSc⁴

¹Department of Pediatrics and Communicable Diseases, Division of Pediatric Hematology and Oncology, University of Michigan, Ann Arbor, MI
²Hematology-Oncology Clinical Research Group, Division of Hematology, St. Michael's Hospital and University of Toronto, Toronto, ON, Canada
³Star Therapeutics, Inc., South San Francisco, CA
⁴Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta and Department of Pediatrics, Emory University, Atlanta, GA

3979

Demographic and Clinical Data in 118 Acquired Hemophilia a: Results from a Single Center Study

Hu Yingying^1,2^*, Xuan Zhou³^*, Shuhua Li, MD⁴^*, Jing Sun⁵^*, Jieyu Ye, PhD⁶^*, Qifa Liu, MD^7,8,9,10 and Houmei Feng¹¹^*

¹Southmedical University Nanfang hospital, Guangzhou, AL, China
²Southmedical University Nanfang hospital, guangzhou, China
³Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
⁴Southern medical university, guangzhou, China
⁵Nanfang Hospital Southern Medical University, Guangzhou, China
⁶Nanfang Hospital,Southern Medical University, Guangzhou, CHN
⁷Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China
⁸Department of Bone Marrow Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang, China
⁹Department of Hematology, Nanfang Hospital, Southern medical university CN, Guangzhou, China
¹⁰Nanfang Hospital, Southern Medical University, Guangzhou, China
¹¹Southmedical Univeisity Nanfang hospital, guangzhou, China

3980

Diagnosis and Disease Burden of Von Willebrand Disease in a Large US Population Based-Dataset

Michelle Sholzberg, MDCM, MSc¹, Angela C Weyand, MD², Jacob S Lai, PhD³^*, Benjamin Kim, MD, MPhil³, Gary Patou, MD³^*, Nicole M. Engel-Nitz, PhD, MS⁴^*, Qiana Amos, PhD, MPH⁴^* and Robert F. Sidonio, Jr., MD, MSc⁵

¹Hematology-Oncology Clinical Research Group, Division of Hematology, St. Michael's Hospital and University of Toronto, Toronto, ON, Canada
²Department of Pediatrics and Communicable Diseases, Division of Pediatric Hematology and Oncology, University of Michigan, Ann Arbor, MI
³Star Therapeutics, Inc., South San Francisco, CA
⁴HEOR, Optum, Eden Prairie, MN
⁵Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta and Department of Pediatrics, Emory University, Atlanta, GA

3981

A Phase Ia Study of VGA039, a Protein S-Targeting Monoclonal Antibody, in Individuals with Von Willebrand Disease Demonstrates Concentration-Dependent Increases in Thrombin Generation for Reducing Bleeding

Carolyn M Millar, MD, PhD^1,2^*, Priyanka Raheja, MBBS, MD³^*, Allison P Wheeler, MD/MSCI⁴, Shrinath Kshirsagar, MD, MBBS⁵^*, Christian Schoergenhofer, MD, PhD⁶^*, Nicoletta C Machin, DO^7,8, Cihan Ay⁹^*, Almudena Tercero, PharmD¹⁰^*, Hayley Lane¹⁰^*, Christopher J Horvath, DVM, MS¹⁰^*, Sandip Panicker, PhD¹⁰, Gary Patou, MD¹⁰^*, Benjamin Kim, MD, MPhil¹⁰ and Savita Rangarajan, MD^11,12

¹Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom
²Imperial College Healthcare NHS Trust, London, United Kingdom
³The Royal London Hospital Haemophilia Centre, Barts Health NHS Trust, London, United Kingdom
⁴Washington Center for Bleeding Disorders, Division of Pediatric Hematology/Oncology & Division of Hematology and Oncology, University of Washington School of Medicine, Seattle, WA
⁵Advanced Center for Research in Oncology, Hematology and Rare Disorders (ACOHRD), K J Somaiya Medical College and Research Centre, Mumbai, Maharashtra, India
⁶Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
⁷Hemophilia Center of Western Pennsylvania, Pittsburgh, PA
⁸Division of Classical Hematology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA
⁹Department of Medicine I, Clinical Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
¹⁰Star Therapeutics, Inc., South San Francisco, CA
¹¹University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
¹²Hematology Laboratory, K J Somaiya Hospital and Research Centre, Mumbai, India

3982

Factor VIII Coagulant Activity (FVIII:C) As an Independent Predictor of Bleeding across Different Subtypes of Von Willebrand Disease (VWD)

Shruti Vilas Kharat, MSc¹^*, Nayaab Khan, PhD²^*, Alina He²^*, Chris Foo, PharmD²^*, Kranti Patil, B.Sc³^*, Gurpreetkaur Saini, M.Sc³^*, Shreyas Tawde, M.Sc³^*, Benjamin Kim, MD, MPhil², Savita Rangarajan, MD³ and Shrimati Shetty, PhD³^*

¹Hematology Laboratory, K J Somaiya Hospital and Research Centre, Mumbai, AL, India
²Star Therapeutics, Inc., South San Francisco, CA
³Hematology Laboratory, K J Somaiya Hospital and Research Centre, Mumbai, India

3983

Association of Blood Type with Von Willebrand Disease Severity Among Patients at an Academic Hemophilia Treatment Center

Drake Kienzle, BA¹^*, Eliakim Munda, BS²^*, Constantine Daskalakis, ScD³^* and Ruben Rhoades, MD²

¹Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA
²Division of Hematology, Department of Medicine, Cardeza Foundation for Hematologic Research, Thomas Jefferson University, Philadelphia, PA
³Division of Biostatistics & Bioinformatics, Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, PA

3984

Rondaptivon Pegol (BT200) to Correct Thrombocytopenia in a Peri-Interventional Setting in Type 2B Von Willebrand Disease (VWD)

Miriam Moser, MD¹^*, Cihan Ay^2,3^*, Christian Schoergenhofer, MD, PhD⁴^*, James C Gilbert, MD⁵^*, Shuhao Zhu, PhD⁶^* and Bernd Jilma, MD⁷

¹Division of Infectious Diseases, Medical University of Vienna, Vienna, Austria
²Division of Hematology, Medical University of Vienna, Vienna, Austria
³Department of Medicine I, Clinical Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
⁴Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
⁵Band Therapeutics, LLC, Lexington, MA
⁶Band Therapeutics LLC, a Guardian Therapeutics company., Lexington, MA
⁷Department of Clinical Pharmacology, Medical University of Vienna, Wien, Austria

3985

Efficacy and Safety of Prophylaxis with a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate Among Von Willebrand Disease Patients across All ABO Antigen Blood Groups

Robert F. Sidonio, Jr., MD, MSc

Department of Pediatrics, Emory University School of Medicine, Atlanta, GA

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH